Table 3.
Doubly-robust estimation of overall survival with multivariate Cox proportional hazards modeling of the propensity-score weighted cohort.
| HR | 95% CI | P | |
|---|---|---|---|
| Local therapy | |||
| LTA | Reference | ||
| SBRT | 0.71 | 0.59–0.85 | < .001 |
| Age | 1.01 | 1.00–1.02 | .003 |
| Sex | |||
| Male | Reference | ||
| Female | 0.79 | 0.67–0.93 | .005 |
| Race | |||
| Caucasian | Reference | ||
| Other | 0.61 | 0.48–0.76 | < .001 |
| Charlson comorbidity score | |||
| 0 | Reference | ||
| ≥ 1 | 1.07 | 0.91–1.26 | .391 |
| Facility Type | |||
| Other | Reference | ||
| Academic | 1.08 | 0.90–1.31 | .412 |
| Facility treatment volume | |||
| Lowest 90% | Reference | ||
| Highest 10% | 0.77 | 0.63–0.94 | .010 |
| Tumor size, cm | |||
| ≤ 2.0 | Reference | ||
| 2.1-3.0 | 1.21 | 1.00–1.46 | .051 |
| 3.1-5.0 | 1.76 | 1.15–2.71 | .010 |
| Histology | |||
| Squamous cell carcinoma | Reference | ||
| Adenocarcinoma | 0.83 | 0.70–1.00 | .050 |
| Grade | |||
| Well-differentiated | Reference | ||
| Moderately-differentiated | 1.39 | 1.02–1.89 | .035 |
| Poorly-differentiated | 1.48 | 1.08–2.03 | .015 |
| Clinical T stage | |||
| cT1 | Reference | ||
| cT2 | 1.02 | 0.68–1.54 | .922 |
| Year of diagnosis | 1.03 | 0.99–1.08 | .108 |
Note: Age (per year) and year of diagnosis (per year) were treated as continuous variables.
Abbreviations: HR, hazard ratio; CI, confidence interval; LTA, local tumor ablation; SBRT, stereotactic body radiotherapy; cm, centimeter; Clinical T Stage, clinical tumor stage as per American Joint Committee on Cancer 6th or 7th Edition.